STING antagonist / Curadev, Bayer - LARVOL DELTA

COMPOUND 2 is a first-in-class small molecule cGAMP competitive oral STING antagonist that reduces neuroinflammation in mouse models (IMMUNOLOGY 2024) - "Once a day oral administration of COMPOUND 2 provided protection from neurodegeneration, decreased striatal tyrosine hydroxylase expression and led to a recovery in dopamine levels in MPTP treated mice. Conclusions COMPOUND 2 is an orally administered novel first-in-class cGAMP competitive STING antagonist with high levels of brain exposure and is a promising candidate for the treatment of neuroinflammatory conditions."

Late-breaking abstract • Preclinical • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • STING

COMPOUND 1 is a first-in-class small molecule cGAMP competitive oral STING antagonist that reduces lung inflammation and fibrosis in chronic bleomycin and silica mouse models (IMMUNOLOGY 2024) - "Orally administration of the compound was well tolerated at high doses in a 14-day non-GLP rat safety study. Conclusions COMPOUND 1 is an orally administered novel first-in-class cGAMP competitive STING antagonist with promising single agent anti-inflammatory and anti-fibrotic activity in chronic lung injury models making it is well suited for IND directed studies."

Late-breaking abstract • Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • STING